Kornimate/medical-research-clean huggingface dataset:
swiss evaluation of bioabsorbable polymer-coated everolimus-eluting coronary stent

Conditions: Coronary Artery Disease

Summary: bioresorbable polymer drug eluting stents (des) are an indisputable improvement over first-generation des with promising results on long-term adverse events. but the thicker polymer and/or strut may hinder its deliverability. complex procedures challenge stent deliverability and stent delivery failure impacts clinical prognosis. this registry aimed to assess the immediate performance of the third-generation synergy everolimus-eluting stent (sees) and its 12-month clinical follow-up in an all-comer population.

all consecutive patients treated with the synergy stent at our institutions were prospectively included in the sweet registry. baseline and procedural characteristics were collected at index procedure. clinical follow-up was performed at 1 month and 1 year by clinic visit or follow-up call. the study end point was a composite of cardiac death (cd), myocardial infarction (mi) and target lesion revascularization (tlr) at 1 year.

Eligibility criteria:
inclusion criteria: 1.patient treated by everolimus-eluting synergy® stent exclusion criteria: 1. patient or legal guardian won't give consent to use collected data

Keywords: des sdf mace synergy
early phase pre-clinical and initial clinical research on epicatechin

Conditions: Pre-diabetes

Summary: early phase pre-clinical and initial clinical research on (+)- epicatechin.

this project is a double-blinded randomized phase i study that will include dose-ranging one day pk and pharmacodynamic (pd) studies. subjects will include healthy individuals and subjects who meet the american diabetes association (ada) criteria for pre-diabetes, including ifg.

Eligibility criteria:
inclusion criteria: * healthy or pre-diabetic based on medical history * male or female * must be 21 to 75 years of age (inclusive) * able to give informed consent to the procedures * if female, must be either postmenopausal or test negative for pregnancy at screening and on the day of the procedure. women on estrogen therapy will be included. * if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study * medication use stable for 4 weeks * body mass index (bmi) \> 27 kg/m\^2 * definition of pre-diabetes: impaired fasting glucose (ifg, fasting glucose = 100-125 mg/dl) and elevated hba1c (5.7-6.4%), each in the absence of other risk factors for diabetes exclusion criteria: * type 2 diabetes * pregnancy * younger than 21 or older than 75 years of age * clinically significant abnormalities in liver or kidney function (\>3x uln), determined in the last 6 months by a certified clinical laboratory * recent mi or stroke (within 6 months of screening) * blood pressure (bp) \>160 mmhg systolic and \>100 mmhg diastolic * medications - thiazolidinediones, any steroids, anti-depressants, weight loss drugs * other diseases, besides type 2 diabetes, influencing carbohydrate metabolism
the prospective study on the effect of ilaprazole in non-erosive reflux disease patients; focused on histologic findings and inflammatory biomarker

Conditions: Gastrointestinal Subepithelial Tumors

Summary: non-erosive reflux disease (nerd) patients used to be less responsive to proton pump inhibitor (ppi)s as compared with patients with erosive esophagitis. the aim of this study is to objectively evaluate the effect of a new ppi, ilaprazole in nerd for adjusting the focus of symptom score, histopathologic findings and inflammatory biomarker. a prospective study performed at single hospital enrolled 20 patients who were diagnosed clinically as nerd. patients underwent egd, a 24hr-combined multichannel intraluminal impedance and ph esophageal monitoring (mii-ph) and were treated with ilaprazole 20mg once daily for 4 weeks. biopsies were obtained from 3cm above the eg junction before and after treatment. gerd q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial t lymphocyte) and inflammatory biomarkers (tnf-α, il-8, il-1β, trpv1 and mcp-1) will be accessed.


Eligibility criteria:
inclusion criteria: * older than 20 years old and younger than 80 years old * patients with typical reflux symptoms at least 2days per week (or gerd q score ≥ 8 ) * no erosion at ge junction through endoscopy * patients that can perform a 24 hr - combined multichannel intraluminal impedance and ph esophageal monitoring prior to this study. exclusion criteria: * included prior history of documented intolerance of ilaprazole or similar ppis, or * unsuspected alarm symptoms such as weight loss, hematemesis, hematochezia, jaundice or other significant illness like malignancy * alcoholism or drug addiction * uncontrolled diabetes, cerebrovascular accident or diseases needed an operation in the last 3 months before enrollment * any previous esophageal surgery * malignancy in gastrointestinal tract within 5years * pregnant woman * zollinger-ellison syndrome, barrett's esophagus, primary esophageal motility abnormality, esophageal stricture, duodenal ulcer, gastric ulcer, pancreatitis, absorption disorder, severe cardiovascular disease, severe lung disease in the last 3 months before enrollment * history of steadily taking medicine such as diazepam, quinidine, diphenylhydantoin, mephenytoin, warfarin, anticholinergic, prostaglandin analog, antineoplastic agent, salicylate, steroid, pro-motility drug, nonsteroidal anti-inflammatory drugs(nsaids) * patients who were registered other exams within 28days * patients who could not conduct sedated endoscopy

Keywords: gastroesophageal reflux, proton pump inhibitors, ilaprazole
effect of 6 weeks of whole-body vibration in treatment of postnatal constipation

Conditions: Constipation

Summary: background: postpartum constipation is a common problem affecting postpartum mothers. aim: to determine whether whole body vibration is effective in treatment of postnatal women constipation. design: the study was designed as a prospective, randomized, single-blind, pre-post-test, controlled trial. hypotheses: it will be hypothesized that: it was hypothesized that whole-body vibration has no or limited effect in treatment of postnatal constipation research question: does whole-body vibration has an effect in treatment of postnatal constipation?

methods: group a received whole-body vibration, pelvic floor exercise and static abdominal exercises interventions for six weeks and group b received pelvic floor exercises and static abdominal exercises in addition to diet instructions in both groups. constipation symptom questionnaire and patient assessment of constipation quality of life questionnaire is applied before and after treatment.

Eligibility criteria:
inclusion criteria: * the participants age ranged from 22 to 35 years old * with vaginal delivery * complain from postnatal constipation from (2 - 6 weeks) post-delivery * had body mass index (bmi) ranged from 30 to 32 kg/m2. exclusion criteria: participants were excluded if they: * had diabetes, hypertension, cardiac diseases. * women who had history of inflammatory bowel disease and abnormalities of anal region or anal fissure * women who had history of bowel surgery (other than appendectomy), * patients who had endocrine disease or digestive tract disease * history of neurological or musculoskeletal disorder.

Keywords: whole body vibration postnatal women
evaluation of a revised indication for determining adult cochlear implant candidacy

Conditions: Hearing Loss

Summary: the sponsor values the progression of hearing healthcare practice and acknowledges a need for re-evaluation of indications for determining adult cochlear implant candidacy. this need arises from current research, peer reviewed literature, and technological advancement with concomitant performance outcomes. to address this specifically, the sponsor proposes to evaluate the safety and efficacy of the cochlear™ nucleus® implant system with a revised indication.

existing research, as discussed, supports the opinion that current candidacy criteria are set conservatively. the sponsor, in addition to the support of recent peer reviewed literature illustrating a need for an appropriate criteria and more suitable speech recognition measure, believe it is appropriate at this time to re-evaluate the candidacy requirements associated with adult cochlear implantation. specifically, this will be accomplished by evaluating the safety and efficacy of the cochlear™ nucleus® cochlear implant system under revised cochlear implant indications. the proposed approach would be to evaluate individuals scoring between 10 - 40% inclusively on consonant nucleus consonant (cnc) monosyllabic words who do not meet current approved speech perception criteria with the widely used sentence measure hearing in noise test (hint) in quiet. no change to current qualifying audiometric criteria (bilateral moderate to profound sensorineural hearing loss in the low frequencies and profound hearing loss in the mid to high speech frequencies) for implant candidacy is proposed.

Eligibility criteria:
inclusion criteria: * eighteen years of age or older at the time of the study. * preoperative aided cnc word score in quiet of greater than or equal to 10% and less than or equal to ¬¬40% in the ear to be implanted; equal to but no better than 50% in the contralateral ear * bilateral moderate to profound hearing loss in the low frequencies (up to 1000 hz) and profound sensorineural hearing loss in the high speech frequencies (3000 hz and above) * willingness to use bimodal stimulation (i.e. a cochlear implant on one ear and a hearing aid on the contralateral ear) through at least 6-months postactivation. * english spoken as the primary language. exclusion criteria: * congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age). * preoperative aided hint sentence score less than or equal to 50% in the ear to be implanted * ossification, absence of cochlear development or any other cochlear anomaly that might prevent complete insertion of the electrode array. * hearing loss of neural or central origin (e.g., deafness due to lesions on the acoustic nerve or central auditory pathway). * active middle-ear infection. * unwillingness and/or inability of the candidate to comply with all investigational requirements including, but not limited to, study protocol and surgical procedure.
analysis of the effectiveness of the use of glycine powder and angled implant brush in oral hygiene maintenance in patients reinstated with columbus bridge protocoltm

Conditions: Plaque, Dental

Summary: this study aims at comparing different procedures of professional oral hygiene (poh) and domiciliary oral hygiene (doh) in columbus bridge protocoltm full-arch reinstated patients by dividing a sample of at least 74 patients into 4 groups with a 1:1:1:1 ratio. the patients will randomly be assigned to a "standard" or "glycine perio flow" professional treatment, and to a "standard" or "angled" toothbrush for their domiciliary oral hygiene. data about bacterial plaque presence is collected both before and after unscrewing the denture, when it comes to implant abutments. instead, denture plaque index will be collected after unscrewing the denture, by means of erythrosine and analyzed using a specific software that allows to compute the percentage of plaque on the denture. patients will be seen after 3 months in order to figure out differences between doh groups, by measuring plaque on abutments and on the denture after unscrewing it. at the moment there are no scientific studies trying to determine which professional and domiciliary procedures might be more efficient to control bacterial plaque in columbus bridge protocoltm reinstated patients. statistically significant lower plaque index (pi) and denture plaque index (dpi) scores are expected in patients treated with glycine perio flow, compared to standard treated patients. however, when it comes to angled toothbrush, lower pi and dpi are expected not to be statistically significant. expectation from this study is to get information on how to improve full-arch patients' therapy in order to reduce peri-implant diseases which are related to bacterial plaque.


Eligibility criteria:
inclusion criteria: * age \>= 18years * good systemic health, with asa classification \<= 2 * columbus bridge protocoltm reinstation from at least six months exclusion criteria: * heavy smokers (\>= 10 cigarettes per day) * pregnancy or breastfeeding * autoimmune diseases with or without oral involvement * biological complications on at least one of the dental implants * perimplantits diagnosis, defined according to lindhe et al's criteria \[5\] * radicular bone \<4mm, evaluated by means of rx * use of gingival overgrowth inducing drugs * cognitive or motor impairments * full-arch reinstations performed in other structures * respiratory issues * infective diseases

Keywords: glycine airflow full-arch angled toothbrush
correlating protection against malaria with serum profiles against plasmodium falciparum antigen repertoires

Conditions: Malaria; Schistosomiasis; Hiv Infection

Summary: a longitudinal study on immune responses in relation to protection against clinical malaria episodes will be conducted in apac district, uganda. three cohorts will be recruited: children 1 to 5 years of age (n=250), children 6 to 10 years of age (n=125) and adults 25 and above (n=125). after finger prick sampling (\~300µl) and examination at enrolment, participants will be followed up for one year. follow-up will include fortnightly active case detection and three-monthly cross-sectional surveys. clinical malaria attacks and the associated clinical and parasitological parameters will be related to immunological profiles determined utilizing a protein microarray as a capture substratum to profile the humoral immune response against a vast number of parasite antigens. for individuals who experience a clinical malaria attack or who are diagnosed with high density parasitaemia (≥15,000 parasites/µl) during cross-sectional surveys, a 5ml blood sample is obtained to determine the diversity of parasite antigens in the population in relation to antigen recognition in the cohort.


Eligibility criteria:
inclusion criteria: * age 1-5 years, 6-10 years or 25 yearsand above * written informed consent must be given * the individual must have been resident of the area since birth or for a minimum period of two years * the individual must be willing to submit required information and to participate in repeated sampling (total blood volume \~2.5 ml over a period of 12 months) * absence of danger signs (as defined by who) or clinical features of aids. an hiv-test will be offered to all participants at enrolment and completion of the study. exclusion criteria: * unwillingness to sign consent form * unwillingness to reside in the study area during the follow-up period
the effects of anticholinergic burden on daily living activities in elderly patients

Conditions: Anticholinergic Syndrome; Anticholinergic Adverse Reaction; Antispasmodic Adverse Reaction; Antiarrhythmic Drug Adverse Reaction; Antiparkinsonism Drugs Causing Adverse Effects in Therapeutic Use; Psychotropic Agents Causing Adverse Effects in Therapeutic Use

Summary: the anticholinergic burden was calculated based on the medications that the patients had used for more than 10 days. short-term medications used by patients were not evaluated. among all the medications used by the patients, those with anticholinergic effects were scored according to the scale, and the total anticholinergic burden was calculated by adding them up. those who had no anticholinergic score were considered to have no anticholinergic burden. the study cohort will be stratified into two cohorts, distinguished by the presence or absence of anticholinergic burden. to evaluate the impact of anticholinergic burden on daily living activities and instrumental adl, the groups will be compared with respect to hand grip strength and walking speed.in this study, the anticholinergic burden will be calculated based on medications used by the patients for more than 10 days, excluding short-term medications. each medication with anticholinergic effects will be assigned a score according to a scale, and the total anticholinergic burden will be determined by summing up the scores. patients without any anticholinergic score will be classified as having no anticholinergic burden. the study cohort will be divided into two groups based on the presence or absence of anticholinergic burden. to assess the impact of anticholinergic burden on daily living activities (adls) and instrumental adls, the groups will be compared in terms of hand grip strength and walking speed.


Eligibility criteria:
inclusion criteria: * being over 65 years old * patients without a diagnosis of dementia and with mmse\>24 * patients who can communicate (without hearing or visual problems) * those who give written consent to participate in the study exclusion criteria: * patients with a diagnosis of dementia at their initial visit, * bedridden patients (those with visual impairments) * patients with walking difficulties (due to pain, prostheses, visual problems, etc.), vitamin d deficiency (10) (20ng/dl\>) or those who use assistive devices (walker, cane, etc.) or those with sequelae of cerebrovascular events or hip fractures. * patients with a diagnosis of delirium, * those who underwent major surgery in the last 6 months, * those who experienced cardiac or cerebrovascular events during the follow-up period, * patients with infectious diseases, * those who did not sign or withdrew their consent form.

Keywords: anticholinergic burden daily living activities geriatrics
anorexia in children with burn injury and the reactions of the immune and endocrine systems

Conditions: Burns; Anorexia

Summary: anorexia in children with burn injury is a common phenomenon. the study is searching for the origin of the anorexia in those children. the study correlates between the level peptides of the immune and the endocrine systems and the length of the anorexia.

burn injury lead to hypermetabolic set to heal the damaged tissue.burn healing uses high energy consumption and as consequence is highly there is a huge activation of the endocrine system and immune system resulting a proinflamtory status. the nutrition component has an important role in the burn healing process by reducing the healing time and also in the quality of the scar tissue. it's been observed that many burn injury patients are suffering from anorexia. since we know pro-inflammatory status modulate satiety rises the question is there a correlation between the level peptides of the immune and the endocrine systems to anorexia in children with burn injury. catecholamines serum concentrations rise following a burn injury. these hormones have an important role in determining the basal metabolic rate (bmr). during the healing process the levels of growth hormone (gh) and insulin like growth factor i (igf-1) are reduced. previous studies show a correlation between these lower levels and interleukins and cytokines such as tumor necrosis factor (tnf) interleukin-6 (il-6). additional hormones, which are relevant, are cortisol and insulin. cortisol levels are very high after severe burn injuries for a long period. insulin sensitivity state also has an important role in the healing process. tnfa and il-6, which are inflammatory factors, found to have significantly elevated serum concentrations during the healing process. they are also known to be reducers to gh sensitivity and causes anorexia. this study will show the connection between the immune and the endocrine systems to the burn healing process and anorexia by examining the level of hormones, interleukins and neuropeptide during the burn healing. our goal is to try and improve the treatment in children with burn injury by nutritional or drug intervention.

Eligibility criteria:
inclusion criteria: * age below 16 years * abilty to feed yourself during hospitalization * gaining consciousness during hospitalization

Keywords: burns anorexia neuropeptide leptin adiponectin gherlin
pilot study of a suprachoroidal retinal prosthesis

Conditions: Retinitis Pigmentosa; Choroideremia

Summary: this study will be an initial proof of concept study, to evaluate safety and efficacy of a prototype suprachoroidal retinal implant


Eligibility criteria:
inclusion criteria: * aged 18 years or older * either gender * a confirmed history of outer retinal degenerative disease such as retinitis pigmentosa or choroideremia * remaining visual acuity of bare light perception or less in both eyes * functional inner retina (ganglion cells and optic nerve), as shown by the ability to perceive light and/or a measurable corneal electrically evoked visual response * a history of at least 10 years of useful form vision in the worse seeing eye * must be willing and able to comply with the testing and follow-up protocol demands (preferably residing within 1.5 hours of the investigational site) exclusion criteria: * optic nerve disease (history of glaucoma of more than 1 month, or history of any other optic neuropathy) * diseases of the inner retina including, but not limited to, central retinal artery or vein occlusion (crao, crvo), end stage diabetic retinopathy, retinal detachment, traumatic retinal damage, infectious retinal disease, inflammatory retinal disease. * inability to visualise the retina due to corneal or other ocular media opacities (corneal degenerations, dense cataracts, trauma, lid malpositions) * any ocular condition that predisposes the subject to rubbing their eyes * cognitive deficiencies, including dementia or progressive neurological disease * psychiatric disorders, including depression, as diagnosed by a qualified psychologist * deafness or significant hearing loss * inability to speak or understand english * pregnancy * presence of a cochlear implant * subject enrolled in another investigational drug or device trial for the treatment of their ocular condition * poor general health, which would exclude them from obtaining a general anaesthetic * unrealistic expectations of the bionic eye device
erector spinae plane block versus paravertebral block during non-intubated thoracoscopic lung resections.

Conditions: Lung Neoplasms

Summary: a randomized prospective trial to test the non-inferiority of erector spinae plane block (espb) in comparison with paravertebral block during non-intubated thoracoscopic lung resection

a prospective randomized trial which aims to evaluate a new technique of peripheral nerve block for pain management, the erector spinae plane block (espb) in patients undergoing minimally invasive lung resection in spontaneous breathing, with intravenous sedation ("non-intubated thoracic surgery"). espb will be compared with a largely employed procedure for loco regional pain management: the paravertebral block (pb). both procedures are performed under ultrasonographic guidance to allow proper visualization of the target site. surgery is carried out by means of a minimally invasive approach (video assisted thoracic surgery) with two keyhole incisions on the affected side.

Eligibility criteria:
inclusion criteria: wedge resection of pulmonary nodules performed with a two-portal or three-portal vats approach. peripheral (within 3 cm from the surface of the inflated lung) nodules, less than 2 cm in diameter. acceptance of awake vats with written informed consent exclusion criteria: age \< 18 years patients who are pregnant or lactating morbid obesity (bmi \> 35 ) inability to understand and sign the informed consent proven allergy to local anesthetic drugs as required by this protocol expected pleural adhesions (previous thoracic trauma, previous pleuro-pulmonary infection, redo surgery on the affected side)

Keywords: awake thoracic surgery, erector spinae plane block